AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AKTS · NASDAQ · Biotechnology

Aktis Oncology

Develops targeted radiopharmaceuticals for solid tumors using miniprotein radioconjugates.

$25.78

After-hours close+0.02 (+0.06%)

At close$25.77(−1.59%)

Date	Estimate	Reported	Surprise
Nov 2026	−$0.45	—	—
Aug 2026	−$0.43	−$0.44	−2.2%
Jun 2026	−$0.33	—	—
May 2026	−$0.31	−$0.38	−22.6%
Mar 2026	−$21.59	−$18.19	+15.8%

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise
Nov 12, 2026	−$0.45	—	—	$3.8M	—	—
Aug 13, 2026	−$0.43	−$0.44	−2.2%	$2.7M	$3.4M	+25.4%
Jun 3, 2026	−$0.33	—	—	$1.8M	—	—
May 11, 2026	−$0.31	−$0.38	−22.6%	$1.9M	$3.2M	+67.2%
Mar 30, 2026	−$21.59	−$18.19	+15.8%	$3.3M	$1.9M	−43.0%